The cardiac sarcolemmal ATP-sensitive potassium channel as a novel target for anti-arrhythmic therapy

Pharmacology and Therapeutics

Volumn 120, Issue 1, 2008, Pages 54-70

  Billman, George E ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

ATP sensitive potassium channels; Cardiac action potentials; Cardiac arrhythmias; Cardiomyocytes; Extracellular potassium; Glibenclamide; HMR 1098; HMR 1402; HMR 1883; Myocardial infarction; Myocardial ischemia; Sudden cardiac death; Ventricular fibrillation

Indexed keywords

1 [[5 [2 (5 CHLORO 2 ANISAMIDO)ETHYL] BETA METHOXYETHOXYPHENYL]SULFONYL] 3 METHYLTHIOUREA; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; AMIODARONE; ANTIARRHYTHMIC AGENT; CLAMIKALANT; GLIBENCLAMIDE; HMR 1402; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; LIDOCAINE; MIBEFRADIL; POTASSIUM; POTASSIUM CHANNEL BLOCKING AGENT; QUINIDINE; SULFONYLUREA RECEPTOR; SULFONYLUREA RECEPTOR 1; SULFONYLUREA RECEPTOR 2A; SULFONYLUREA RECEPTOR 2B; UNCLASSIFIED DRUG; VERAPAMIL;

ACTION POTENTIAL; CARDIOSELECTIVITY; CELL SURFACE; CORONARY ARTERY BLOOD FLOW; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; ISCHEMIC PRECONDITIONING; NONHUMAN; PANCREAS ISLET BETA CELL; POTASSIUM TRANSPORT; PRIORITY JOURNAL; REVIEW; SARCOLEMMA; SUDDEN DEATH; SYSTOLIC BLOOD PRESSURE; TREADMILL; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; HUMANS; KATP CHANNELS; MYOCARDIUM; POTASSIUM CHANNEL BLOCKERS; SARCOLEMMA;

EID: 51849154149     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2008.07.004     Document Type: Review

References (183)

1. Abildstrom S.Z., Kobler L., and Torp-Pedersen C. Epidemiology of arrhythmic and sudden death in the chronic phase of ischemic heart disease. Cardiac Electrophysiol Rev 3 (1999) 177-179
2. Aguilar-Bryan L., Nichols C.G., Wechsler S.W., Clement J.P., Boyd A.E., Gonzales G., Herrera-Sosa H., Nguy K., Bryan J., and Nelson D. Cloning of the beta cell high affinity sulfonylurea receptor: a regulator of insulin secretion. Science 268 (1995) 423-426
3. Amiodarone trials meta-analysis investigators. Effects of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomized trials. Lancet 350 (1997) 1417-1424
4. Aronson D., Mittleman M.A., and Burger A.J. Effects of sulfonylurea agents and adenosine triphosphate dependent potassium channel antagonists on ventricular arrhythmias in patients with decompensated heart failure. PACE 26 (2003) 1254-1261
5. Baczko I., Lepran I., and Papp J.G. KATP channel modulators increase survival rate during coronary occlusion-reperfusion in anaesthetized rats. Eur J Pharmacol 324 (1997) 77-83
6. Barrett T.D., and Walker M.J. Glibenclamide does not prevent action potential shortening induced by ischemia in anesthetized rabbits but reduces ischemia-induced arrhythmias. J Mol Cell Cardiol 30 (1998) 999-1008
7. Bayes de Luna A., Coumel P., and LeClercq J.F. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 117 (1989) 151-159
8. Behrens S., Zabel M., Janssen A., Barbierato M., and Schultheiss H.P. Influence of a new ATP-sensitive potassium-channel antagonist (HMR 1098) on ventricular fibrillation inducibility during myocardial ischemia. Eur Heart J 22 abstract suppl (2001) 546
9. Bekheit S.S., Restivo M., Boutjdir M., Henkin R., Gooyandeh K., Assadi M., Khatib S., Gough W.B., and El-Sherif N. Effects of glyburide on ischemia-induced changes in extracellular potassium and local myocardial activation: a potential new approach to the management of ischemia-induced malignant ventricular arrhythmias. Am Heart J 119 (1990) 1025-1033
10. + channel modulators on an ischemia-reperfusion rabbit isolated heart model with programmed electrical stimulation. Eur J Pharmacol 256 (1994) 115-124
11. Benndorf K., Friedrich M., and Hirche H. Anoxia opens ATP regulated K channels in isolated heart cells of the guinea pig. Pflugers Arch 419 (1991) 108-110
12. Billman G.E. The antiarrhythmic and antifibrillatory effects of calcium antagonists. J Cardiovasc Pharmacol 18 Suppl 10 (1991) S107-S117
13. Billman G.E. Ro 40-5967, a novel calcium channel antagonist protects against ventricular fibrillation. Eur J Pharmacol 229 (1992) 179-187
14. Billman G.E., and Hamlin R.L. The effect of a novel calcium channel antagonist, mibefradil, on refractory period and arrhythmias induced by programmed electrical stimulation and myocardial ischemia: a comparison with diltiazem and verapmil. J Pharmacol Exp Therap 277 (1995) 1517-1526
15. Billman G.E., Avendano C.E., Halliwill J.R., and Burroughs J.M. The effects of the ATP-dependent potassium channel antagonist glyburide on coronary blood flow and susceptibility to ventricular fibrillation. J Cardiovasc Pharmacol 21 (1993) 197-204
16. + accumulation and cardiac arrhythmias during myocardial ischemia. Cardiovasc Res 28 (1994) 762-769
17. Billman G.E., Englert H.C., and Schoelkens B.A. HMR 1883, a novel cardioselective inhibitor of the ATP- sensitive potassium channel; Part II: effects on susceptibility to ventricular fibrillation induced by myocardial ischemia in conscious dogs. J Pharmacol Exp Therap 286 (1998) 1465-1473
18. Billman G.E., Houle M.S., Englert H.C., and Goegelein H. Ischemically-induced changes in the T-wave and susceptibility to sudden death: evidence that activation of the ATP-sensitive potassium channel may contribute to ventricular fibrillation. Circulation 100 Suppl I (1999) I-52
19. Billman G.E., Englert H.C., Goegelein H., and Busch A. Selective sarcolemmal, but not selective mitochondrial, ATP-sensitive potassium channel antagonists prevent ventricular fibrillation induced by ischaemia. Eur Heart J 22 abstract suppl (2001) 246
20. Billman G.E., Houle M.S., Englert H.C., and Gögelein H. Effects of a novel cardioselective ATP-sensitive potassium channel antagonist 1-[[5-[2(5-chloro-o-anisamido)ethyl]-β-methoxyethoxyphenyl]sulfonyl ]-3-methylthioura, sodium salt (HMR 1402), on susceptibility to ventricular fibrillation induced by myocardial ischemia: in vitro and in vivo studies. J Pharmacol Exp Therap 309 (2004) 182-192
21. ATP channel blocker HMR 1883 attenuates the effects of ischemia on MAP duration and improves survival during LAD occlusion in anaesthetized pig. Br J Pharmacol 124 (1998) 23P
22. Bril A., Laville M.P., and Gout B. Effects of glibenclamide on ventricular arrhythmias and cardiac function in ischaemia and reperfusion in isolated rat heart. Cardiovasc Res 26 (1992) 1069-1076
23. Buxton A.E., Lee K.L., Fisher J.D., Josephson M.E., Prystowsky E.N., and Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 341 (1999) 1882-1890
24. Cacciapuoti F., Spiezia R., Bianchi M., Lama D., D'Avino M., and Varricchio M. Effectiveness of glibenclamide on myocardial ischemic ventricular arrhythmias in non-insulin dependent diabetes mellitus. Am J Cardiol 67 (1991) 843-847
25. Chi L., Black S.C., Kuo P.I., Fagbemi S.O., and Lucchesi B.R. Actions of pinacidil at a reduced potassium concentration - a direct cardiac effect possibly involving the ATP-sensitive potassium channel. J Cardiovasc Pharmacol 21 (1993) 179-190
26. Chi L., Uprichard A.C.G., and Lucchesi B.R. Profibrillatory actions of pinacidil in a conscious canine model of sudden coronary death. J Cardiovasc Pharmacol 15 (1990) 452-464
27. ATP channels enhances insulin-stimulated glucose uptake in skeletal muscle. Proc Natl Acad Sci (USA) 98 (2001) 11760-11764
28. Colatsky T.J., Follmer C.H., and Starmer C.F. Channel specificity in antiarrhythmic drug action. Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation 82 (1990) 2235-2242
29. ATP channel activation. Circulation 105 (2002) 2309-2317
30. Coronel R., Fiolet J.W., Wilms-Schopman F.J., Schaapherder A.F., Johnson T.A., Gettes L.S., and Janse M.J. Distribution of extracellular potassium and its relation to electrophysiologic changes during acute myocardial ischemia in the isolated perfused porcine heart. Circulation 77 (1988) 1125-1138
31. Coronel R., Wilms-Schopman F.J., Dekker L.R., and Janse M.J. Heterogeneities in [K+]o and TQ potential and the inducibility of ventricular fibrillation during acute regional ischemia in the isolated perfused porcine heart. Circulation 92 (1995) 120-129
32. Coronel R., Wilms-Schopman F.J., Opthof T., van Capelle F.J., and Janse M.J. Injury current and gradients of diastolic stimulation threshold, TQ potential, and extracellular potassium concentration during acute regional ischemia in the isolated perfused pig heart. Circ Res 68 (1991) 1241-1249
33. Curtis M.J. The rabbit dual coronary perfusion model: a new method for assessing pathological relevance of individual products of the ischaemeic milieu: role of potassium in arrhythmogenesis. Cardiovasc Res 25 (1991) 1010-1022
34. Curtis M.J., Pugsley M.K., and Walker M.J.A. Endogenous chemical mediators of ventricular arrythmias in ischaemic heart disease. Cardiovasc Res 27 (1993) 703-719
35. D'Alonzo A.J., Zhu J.L., Darbenzio R.B., Dorso C.R., and Grover G.J. Proarrhythmic effects of pinacidil are partially meditated through enhancement of catecholamine release in isolated perfused guinea-pig hearts. J Mol Cell Cardiol 30 (1998) 415-423
36. ATP channel activation important in the antiarrhythmic and cardioprotective effects during acute ischemia/reperfusion in the intact anesthetized rabbit model?. Life Science 77 (2005) 1226-1248
37. Davis T.M., Parsons R.W., Broadhurst R.J., Hobbs M.S., and Jamrozik K. Arrhythmias and mortality after myocardial infarction in diabetic patients. Relationship to diabetes treatment. Diabetes Care 21 (1998) 637-640
38. del Valle H.F., Lascano E.C., Negroni J.A., and Crottogini A.J. Glibenclamide effects reperfusion-induced malignant arrhythmias and left ventricular mechanical recovery from stunning in conscious sheep. Cardiovasc Res 50 (2001) 474-485
39. + current during hypoxia: correlation with tissue ATP levels. Am J Physiol Heart Circ Physiol 261 (1991) H671-H676
40. K.ATP blockers glibenclamide and HMR1883 on cardiac electrophysiology during ischemia and reperfusion. Eur J Pharmacol 398 (2000) 273-284
41. Di Diego J.M., and Antzelevitch C. Pinacidil-induced electrical heterogeneity and extrasystolic activity in canine ventricular tissues. Does activation of ATP-regulated potassium current promote phase 2 reentry. Circulation 88 (1993) 1177-1189
42. + channels that are inhibited by ATP in an insulin secreting cell line. FEBS Lett 208 (1986) 59-62
43. Echt D.S., Liebson P.R., Mitchell L.B., Peters R.W., Obiasmanno D., Barker A.H., Arensberg D., Baker A., Freedman L., Greene H.L., Hunter M.L., and Richardson D.W. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 324 (1991) 782-788
44. Edwards G., and Weston A.H. The pharmacology of ATP-sensitive potassium channels. Ann Rev Pharmacol Toxicol 33 (1993) 597-637
45. El Reyani N.E., Bozdogan O., Baczko I., Lepran I., and Papp J.G. Comparison of the efficacy of glibenclamide and glimepiride in reperfusion-induced arrhythmias in rats. Eur J Pharmacol 365 (1999) 187-192
46. Englert H.C., Gerlach U., Goegelein H., Hartung J., Heitsch H., Mania D., and Scheidler S. Cardioselective K(ATP) channel blockers derived from a new series of m-anisamidoethylbenzenesulfonylthioureas. J Med Chem 44 (2001) 1085-1098
47. Englert H.C., Heitsch H., Gerlach U., and Knieps S. Blockers of the ATP-sensitive potassium channel SURA/Kir6.2: a new approach to prevent sudden cardiac death. Curr Med Chem 1 (2003) 253-271
48. Faivre J.F., and Findlay I. Action potential duration and activation of ATP-sensitive potassium current in isolated guinea-pig ventricular myocytes. Biochim Biophys Acta 1029 (1990) 167-172
49. Findlay I. ATP4- and ATP.Mg inhibit the ATP-sensitive K+ channel of rat ventricular myocytes. Pflugers Arch 412 (1988) 37-41
50. Fischbach P.S., White A., Barrett T.D., and Lucchesi B.R. Risk of ventricular proarrhythmia with the selective opening of the myocardial sarcolemmal versus mitochondrial ATP-gated potassium channel. J Pharmacol Exp Ther 309 (2004) 554-559
51. ATP channels: what do we really know?. J Mol Cell Cardiol 39 (2005) 61-70
52. Flagg T.P., Patton B., Masia R., Mansfield C., Lopatin A.N., Yamada K.A., and Nichols C.G. Arrhythmia susceptibility and premature death in transgenic mice overexpressing both SUR1 and Kir6.2[DN30,K185Q] in the heart. Am J Physiol Heart Circ Physiol 293 (2007) H836-H845
53. + channels. J Biol Chem 263 (1988) 7933-7936
54. ATP?. Biochem Biophys Res Comm 266 (2008) 649-656
55. Friedel H.A., and Brogden R.N. Pinacidil - a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension. Drugs 39 (1990) 929-967
56. ATP channel in preservation of mitochondrial function. Am J Physiol Heart Circ Physiol 278 (2000) H305-H312
57. Furukawa T., Kimura S., Furukawa N., Bassett A.L., and Myerburg R.J. Role of cardiac ATP-regulated potassium channels in differential responses of endocardial and epicardial cells to ischemia. Circ Res 68 (1991) 1693-1702
58. Gilmour Jr. R.F., and Zipes D.P. Different electrophysiological responses of canine endocardium and epicardium to combined hyperkalemia, hypoxia, and acidosis. Circ Res 46 (1980) 814-825
59. Gillum R. Sudden coronary death in the United States 1980-1985. Circulation 79 (1989) 756-765
60. Gögelein H. Inhibition of cardiac ATP-dependent potassium channels by sulfonylurea drugs. Curr Opin Invest Drugs 2 (2001) 71-80
61. ATP channels. Cell Physiol Biochem 9 (1999) 227-241
62. Gögelein H., Hartung J., Englert H.C., and Scholkens B.A. HMR 1883, a novel cardioselective inhibitor of the ATP-sensitive potassium channel. Part I: effects on cardiomyocytes, coronary flow and pancreatic beta-cells. J Pharmacol Exp Ther 286 (1998) 1453-1464
63. Gok S., Vural K., Sekuri C., Onur R., Tezcan A., and Izanli A. Effects of the blockade of cardiac sarcolemmal ATP-sensitive potassium channels on arrhythmias and coronary flow in ischemia-reperfusion model in isolated rat hearts. Vasc Pharmacol 44 (2006) 197-205
64. Goldberg M.R. Clinical pharmacology of pinacidil, a prototype for drugs that affect potassium channels. J Cardiovasc Pharmacol 12 Suppl 2 (1988) S41-S47
65. ATP channel deficiency affects resting tension, not contractile force, during fatigue in skeletal muscle. Am J Physiol 279 (2000) C1351-1358
66. Gopalakrishnan M., Whiteaker K.L., Molinari E.J., Davis-Taber R., Scott V.E., s., Shieh C.C., Buckner S.A., Milicic I., Cain J.C., Postl S., Sullivan J.P., and Brioni J.D. Characterization of the ATP-sensitive potassium channels (K-ATP) expressed in guinea pig bladder smooth muscle cells. J Pharmacol Exp Ther 289 (1999) 551-558
67. Greene H.L. Sudden arrhythmic cardiac death: mechanisms, resuscitation and classification: the Seattle perspective. Am J Cardiol 65 (1990) 4B-12B
68. Gribble F.M., and Reimann F. Sulphonylurea action revisited: the post-cloning era. Diabetologia 46 (2003) 875-891
69. Gribble F.M., Tucker S.J., and Ashcroft F.M. The essential role of Walker A motifs of SUR1 in K-ATP channel activation by MgADP and diazoxide. EMBO J 16 (1997) 1145-1152
70. ATP channels. Diabetes 47 (1998) 1412-1418
71. + channels and myocardial preconditioning. Circ Res 84 (1999) 973-979
72. Grover G.J., and Garlid K.D. ATP-sensitive potassium channels: a review of their cardioprotective pharmacology. J Mol Cell Cardiol 32 (2000) 677-695
73. ATP opener with no peripheral vosaodilator or cardiac action potential shortening activity. J Phamacol Exp Ther 297 (2001) 1184-1192
74. ATP opener (3R)-trans-4-((4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)dimethyl-2H-1-b enzopyran-6-carbonitril monohydrochloride (BMS-191095): cardioprotective, hemodynamic, and electrophysiological effects. J Pharmacol Exp Ther 303 (2002) 132-140
75. + loss in a model of ischaemia in perfused guinea-pig hearts in vitro. Eur J Pharmacol 220 (1992) 231-236
76. Hamada K., Yamazaki J., and Nagao T. Shortening of monophasic action potential duration during hyperkalemia and myocardial ischemia in anesthetized dogs. Jpn J Pharmacol 76 (1998) 149-154
77. Harris A.S. Potassium and experimental coronary occlusion. Am Heart J 71 (1966) 797-802
78. Harris A.S., Bisteni A., Russell R.A., Brigham J.C., and Firestone J.E. Excitory factors in ventricular tachycardia resulting from myocardial ischemia: potassium a major excitant. Science 119 (1954) 200-203
79. Haworth R.A., Goknur A.B., and Berkoff H.A. Inhibition of ATP-sensitive potassium channels of adult rat heart cells by antiarrhythmic drugs. Circ Res 65 (1989) 1157-1160
80. Held P., and Yusuf S. Early intravenous beta-blockade in acute myocardial infarction. Cardiology 76 (1989) 132-143
81. 2+ channel blockers in acute myocardial infarction. Eur Heart J 14 Suppl F (1993) 18-25
82. Hicks M.N., and Cobbe S.M. Effect of glibenclamide on extracellular potassium accumulation and the electrophysiological changes during myocardial ischaemia in the arterially perfused interventricular septum of rabbit. Cardiovasc Res 25 (1991) 407-413
83. + activity in swine. Circulation 61 (1980) 768-778
84. Hinkle L.E.J., and Thaler H.T. Clinical classification of cardiac deaths. Circulation 65 (1982) 457-464
85. Holmes D.S., Sun Z.Q., Porter L.M., Bernstein N.E., Chinitz L.A., Artman M., and Coetzee W.A. Amiodarone inhibits cardiac ATP-sensitive potassium channels. J Cardiovasc Electrophysiol 11 (2000) 1152-1158
86. Hondeghem L.M. Antiarrhythmic agents: modulated receptor applications. Circulation 75 (1987) 514-520
87. Hondeghem L.M., and Cotner C.L. Reproducible and uniform cardiac ischemia: effects of antiarrhythmic drugs. Am J Physiol Heart Circ Physiol 235 (1978) H574-H580
88. Huizar J.F., Gonzalez L.A., Alderman J., and Smith H.S. Sulfonylureas attenuate electrocardiographic ST-segment elevations during acute myocardial infarction in diabetics. J Am Coll Cardiol 42 (2003) 1017-1021
89. KATP: an inward rectifier subunit plus the sulfonylurea receptor. Science 270 (1995) 1166-1170
90. Johnson T.A., Engle C.L., Boyd L.M., Koch G.G., Gwinn M., and Gettes L.S. Magnitude and time course of extracellular potassium inhomogeneities during acute ischemia in pigs. Effect of verapamil. Circulation 83 (1991) 622-634
91. ATP channel blocker HMR 1883 does not abolish the benefit of ischemic preconditioning on myocardial infarct mass in anesthetized rabbits. Naunyn Schmiedebergs Arch Pharmacol 361 (2000) 445-451
92. Kaab S., Zwermann L., Barth A., Hinterseer M., Englert H.C., Gögelein H.R., and Nabauer M. Selective block of sarcolemmal IKATP in human cardiomycytes using HMR 1098. Cardiovasc Drug Therap 17 (2003) 435-441
93. + channels in rat pancreatic β-cells is modulated by ADP. FEBS Lett 208 (1986) 63-66
94. Kanda A., Watanabe I., Williams M.L., Engle C.L., Li S., Koch G.G., and Gettes L.S. Unanticipated lessening of the rise in extracellular potassium during ischemia by pinacidil. Circulation 95 (1997) 1937-1944
95. + loss and arrhythmias in rat hearts: effect of glibenclamide, a sulfonylurea. Circ Res 66 (1990) 478-485
96. Kempsford R.D., and Hawgood B.J. Assessment of the antiarrhythmic activity of nicorandil during myocardial ischemia and reperfusion. Eur J Pharmacol 163 (1989) 61-68
97. Kendall M.J., Lynch K.P., Hjalmarson A., and Kjekshus J. β-Blockers and sudden cardiac death. Ann Intern Med 123 (1995) 353-367
98. Kimura S., Bassett A.L., Kohya T., Kozlovskis P.L., and Myerburg R.J. Simultaneous recording of action potentials from endocardium and epicardium during ischemia in the isolated cat ventricle: relation of temporal electrophysiologic heterogeneities to arrhythmias. Circulation 74 (1986) 401-409
99. Kleber A.G. Resting membrane potential, extracellular potassium activity, and intracellular sodium activity during acute global ischemia in isolated perfused guinea pig hearts. Circ Res 52 (1983) 442-450
100. Kleber A.G. Extracellular potassium accumulation in acute myocardial ischemia. J Mol Cell Cardiol 16 (1984) 389-394
101. Kondo T., Kubota I., Tachibana H., Yamaki M., and Tomoike H. Glibenclamide attenuates peaked T wave in early phase of myocardial ischemia. Cardiovasc Res 31 (1996) 683-687
102. ATP) connection. Diabetes 54 (2005) 3065-3072
103. Koumi S.I., Martin R.L., and Sato R. Alterations in ATP-sensitive potassium channel sensitivity to ATP in failing human hearts. Am J Physiol Heart Cric Physiol 272 (1997) H1656-H1665
104. + currents activated by metabolic inhibition in rat ventricular myocytes differ from those elicited by the channel opener rilmakalim. Pflugers Arch 429 (1995) 625-635
105. Krumenacker M., and Roland E. Clinical profile of nicorandil - an overview of its hemodynamic properties and therapeutic efficacy. J Cardiovasc Pharmacol 20 Suppl 3 (1992) S93-S102
106. + channel on ECG ST segment elevation during a bout of myocardial ischemia. A study on epicardial mapping in dogs. Circulation 88 (1993) 1845-1851
107. Lepran I., Baczko I., Varro A., and Papp J.G. ATP-sensitive potassium channel modulators: both pinacidil and glibenclamide produce antiarrhythmic activity during acute myocardial infarction in conscious rats. J Pharmacol ExpTher 277 (1996) 1215-1220
108. Li R.A., Leppo M., Miki T., Seino S., and Marban E. Molecular basis of electrocardiographic ST-segment elevation. Circ Res 87 (2000) 837-839
109. ATP channel is a mechanism by which sudden death is produced by low-energy chest-wall impact (Commotio cordis). Circulation 100 (1999) 413-418
110. Liss B., and Roeper J. Molecular physiology of neuronal K-ATP channels. Mol Membr Biol 18 (2001) 117-127
111. Liu Y., Sato T., O'Rourke B., and Marban E. Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection?. Circulation 97 (1998) 2463-2469
112. ATP channels. Mol Pharmacol 59 (2001) 225-230
113. Lomuscio A., and Fiorentini C. Influence of oral antidiabetic treatment on electrocardiac alterations induced by myocardial infarction. Diabetes Res Clin Pract 31 Suppl (1996) S21-S26
114. Lomuscio A., Vergani D., Marano L., Castagnone M., and Fiorentini C. Effects of glibenclamide on ventricular fibrillation in non-insulin-dependent diabetics with acute myocardial infarction. Coron Artery Dis 5 (1994) 767-771
115. MacKenzie I., Saville V.L., and Waterfall J.F. Differential class III and glibenclamide effects on action potential duration in guinea-pig papillary muscle during normoxia and hypoxia/ischaemia. Br J Pharmacol 110 (1993) 531-538
116. Manning-Fox J.E.M., Kanji H.D., French R.J., and Light P.E. Cardioselectivity of the sulphonylurea HMR 1098: studies on native and recombinant cardiac and pancreatic K-ATP channels. Br J Pharmacol 135 (2002) 480-488
117. e changes during ischemia in the rat heart. Am J Physiol Heart Cric Physiol 263 (1992) H333-H340
118. Mitani A., Kinoshita K., Fukamachi K., Sakamoto M., Kurisu K., Tsuruhara Y., Fukumura F., Nakashima A., and Tokunaga K. Effects of glibenclamide and nicorandil on cardiac function during ischemia and reperfusion in isolated perfused rat hearts. Am J Physiol Heart Circ Physiol 261 (1991) H1864-H1871
119. + channel blockers on the action potential shortening in hypoxic and ischaemic myocardium. Br J Pharmacol 103 (1991) 1019-1026
120. Nattel S. Class III drugs: amiodarone, bertylium, ibutilide, and sotalol. In: Zipes D.P., and Jalife J. (Eds). Cardiac electrophysiology from cell to bedside. 3rd Ed. (2000), W. B. Saunders Co, Philadelphia 921-932
121. ATP channels as molecular sensors of cellular metabolism. Nature 440 (2006) 470-476
122. + channel activity in intact and permeabilized rat ventricular myocytes. J Physiol (Lond) 423 (1990) 91-110
123. Nichols C.G., and Lederer W.J. Adenosine triphosphate-sensitive potassium channels in the cardiovascular system. Am J Physiol Heart Circ Physiol 261 (1991) H1675-H1686
124. Nichols C.G., Ripoll C., and Lederer W.J. ATP-sensitive potassium channel modulation of the guinea pig ventricular action potential and contraction. Circ Res 68 (1991) 280-287
125. Nichols C.G., Shyng S.L., Nestorowicz A., Glaser B., Celment IV J.P., Gonzalez G., Aguilar-Bryan L., Permutt M.A., and Bryan J. Adenosine diphosphate as intracellular regulator of insulin section. Science 272 (1996) 1785-1787
126. + channels in cardiac muscle. Nature 305 (1983) 147-148
127. Olschewski A., Brau M.E., Olschewski H., Hempelmann G., and Vogel W. ATP-dependent potassium channel in rat cardiomyocytes is blocked by lidocaine. Possible impact on the antiarrhythmic action of lidocaine. Circulation 93 (1996) 656-659
128. Opie L.H., Nathan D., and Lubbe W.F. Biochemical aspects of arrhythmogenesis. Am J Cardiol 43 (1979) 131-148
129. p-e interval does not reflect transmural dispersion. Heart Rhythm 4 (2007) 341-348
130. ATP channels in preconditioning. Circ Res 87 (2000) 845-855
131. Pasnani J.S., and Ferrier G.R. Differential effects of glyburide on premature beats and ventricular tachycardia in an isolated tissue model of ischemia and reperfusion. J Pharmacol Exp Ther 262 (1992) 1076-1084
132. ATP channel in unstable angina. Eur Heart J. 20 (1999) 51-57
133. Pogatsa G., Koltai M.Z., Balkanyi I., Devai I., Kiss V., and Koszeghy A. The effect of various hypoglycaemic sulphonylureas on the cardiotoxicity of glycosides and arrhythmogenic activity due to myocardial ischaemia. Acta Physiol Hung 71 (1988) 243-250
134. Rau E.E., Shine K.I., and Langer G.A. Potassium exchange and mechanical performance in anoxic mammalian myocardium. Am J Physiol Heart Circ Physiol 232 (1977) H85-H94
135. ATP channel opener, myocardial ischemia and arrhythmias - should the electrophysiologist worry?. Cardiovasc Drug Ther 14 (2000) 17-22
136. Rees S.A., and Curtis M.J. Pharmacological analysis in rat of the role of the ATP-sensitive potassium channels as a potential target fro antifibrillatory intervention in acute myocardial-ischemia. J Cardiovasc Pharmacol 26 (1995) 280-288
137. Rees S.A., Tsuchihashi K., Hearse D.J., and Curtis M.J. Combined administration of an Ik(ATP) activator and Ito blocker increases coronary blood flow independently of effects on heart rate, QT interval, and ischaemai-induced ventricular fibrillation in rats. J Cardiovasc Pharmacol 22 (1993) 343-349
138. Reimann F., Proks P., and Ashcroft F.M. Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel. Br J Pharmacol 132 (2001) 1542-1548
139. Rovetto M.J., Whitmer J.T., and Neely J.R. Comparison of the effects of anoxia and whole heart ischemia on carbohydrate utilization in isolated working rat hearts. Circ Res 32 (1973) 699-711
140. Rubart M., and Zipes D.P. Mechanism of sudden cardiac death. J Clin Invest 115 (2005) 2305-2315
141. + channel blockers on the action potential of hypoxic rabbit myocardium. Br J Pharmacol 106 (1992) 924-930
142. Sager P.T. New advances in class III antiarrhythmic drug therapy. Curr Opin Cardiol 14 (1999) 15-23
143. + cahnnels in electrophysiological alterations during myocardial ischemia: a study using Kir6.2-null mice. Am J Physiol Heart Circ Physiol 288 (2005) H352-H357
144. ATP channels. Circ Res 85 (1999) 1113-1114
145. ATP channels in cardioprotection. Bas Res Cardiol 95 (2000) 285-289
146. ATP channels in ischemic cardioprotection. Circulation 101 (2000) 2418-2423
147. Sato T., Takizawa T., Saito T., Kobayashi S., Hara Y., and Nakaya H. Amiodarone inhibits sarcolemmal but not mitchondrial K-ATP channels in guinea pig ventricular cells. J Pharmacol Exp Therap 307 (2003) 955-960
148. ATP channels, and confers cardioprotection. J Pharmacol Exp Therap 316 (2006) 182-188
149. Schnitzler M.M., Y., Derst C., Daut J., and Preisig-Muller R. ATP-sensitive potassium channels in capillaries isolated from guinea-pig heart. J Physiol (Lond) 525 (2000) 307-317
150. + efflux. Circ Res 74, 829-838.
151. 42K exchange during myocardial ischemia. Am J Physiol Heart Circ Physiol 232 (1977) H564-H570
152. Smallwood J.K., Ertel P.J., and Steinberg M.I. Modification by glibenclamide of the electrophysiological consequences of myocardial ischaemia in dogs and rabbits. Naunyn Schmiedebergs Arch Pharmacol 342 (1990) 214-220
153. Suzuki M., Li R.A., Miki T., Uemura H., Sakamoto N., Ohmoto-Sekine Y., Tamagawa M., Ogura T., Seino S., Marban E., and Nakaya H. Functional roles of cardiac and vascular ATP-sensitive potassium channels clarified by Kir6.2-knockout mice. Circ Res 88 (2001) 570-577
154. Torp-Pedersen C., Kober L., Elming H., and Burchart H. Classification of sudden and arrhythmic death. PACE 20 (1997) 2545-2552
155. Tosaki A., Engelman D.T., Engelman R.M., and Das D.K. Diabetes and ATP-sensitive potassium channel openers and blockers in isolated ischemic/reperfused hearts. J Pharmacol Exp Ther 275 (1995) 1115-1123
156. Trube G., and Hescheler J. Inward-rectifying channels in isolated patches of the heart cell membrane: ATP-dependence and comparison with cell-attached patches. Pfugers Arch 401 (1984) 178-184
157. Tweedie D., Henderson C., and Kane K. Glibenclamide, but not class III drugs, prevents ischaemic shortening of the refractory period in guinea-pig hearts. Eur J Pharmacol 240 (1993) 251-257
158. Uchida T., Yashima M., Gotoh M., Qu Z., Garfinkel A., Weiss J.N., Fishbein M.C., Mandel W.J., Chen P.S., and Karagueuzian H.S. Mechanism of acceleration of functional reentry in the ventricle: effects of ATP-sensitive potassium channel opener. Circulation 99 (1999) 704-712
159. ATP channel inhibition is defibrillatory and improves survival during acute myocardial ischemia and reperfusion. Eur J Pharmacol 577 (2007) 115-123
160. Vanheel B., and De Hemptinne A. Influence of KATP channel modulation on net potassium efflux from ischaemic mammalian cardiac tissue. Cardiovasc Res 26 (1992) 1030-1039
161. + loss during hypoxia, ischemia, and metabolic inhibition in mammalian ventricle. Circ Res 69 (1991) 623-637
162. + loss and cardiac function in ischemic and reperfused mammalian ventricle. Circ Res 71 (1992) 1324-1333
163. Waldo A.L., et al., for the SWORD Investigators. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 348 (1996) 7-12
164. + channel function. Circulation 104 (2001) 2645-2648
165. + loss in hypoxic and ischaemic mammalian ventricle. J Physiol (Lond) 447 (1992) 649-673
166. Weyermann A., Vollert H., Busch A.E., Bleich M., and Gögelein H. Inhibitors of ATP-sensitive potassium channels in guinea pig isolated ischemic hearts. Naunyn Schmiedebergs Arch Pharmacol 369 (2004) 374-381
167. + channel current in ischemic arrhythmias. Cardiovasc Drugs Ther 7 (1993) 521-526
168. KATP during acute myocardial ischaemia: controversies revive. Cardiovasc Res 35 (1998) 181-183
169. Wilde A.M.M., and Aksnes G. Myocardial potassium loss and cell depolarization in ischaemia and hypoxia. Cardiovasc Res. 29 (1995) 1-15
170. Wilde A.A., Escande D., Schumacher C.A., Thuringer D., Mestre M., Fiolet J.W., and Janse M.J. Potassium accumulation in the globally ischemic mammalian heart. A role for the ATP-sensitive potassium channel. Circ Res 67 (1990) 835-843
171. Wirth K.J., Rosenstein B., Uhde J., Englert H.C., Busch A.E., and Scholkens B.A. ATP-sensitive potassium channel blocker HMR 1883 reduces mortality and ischemia-associated electrocardiographic changes in pigs with coronary occlusion. J Pharmacol ExpTher 291 (1999) 474-481
172. Wirth K.J., Klaus E., Englert H.G., Scholkens B.A., and Linz W. HMR 1883, a cardioselective K(ATP) channel blocker, inhibits ischaemia- and reperfusion-induced ventricular fibrillation in rats. Naunyn Schmiedebergs Arch Pharmacol 360 (1999) 295-300
173. ATP channel blocker HMR 1883 reduces monophasic action potential shortening during coronary ischemia in anesthetised pigs. Naunyn Schmiedebergs Arch Pharmacol 361 (2000) 155-160
174. Wit A.L., and Janse M.J. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev 69 (1989) 1049-1169
175. Wolk R., Cobbe S.M., Kane K.A., and Hicks M.N. Relevance of inter- and intraventricular electrical dispersion to arrhythmogenesis in normal and ischaemic rabbit myocardium: a study with cromakalim, 5-hydroxydecanoate and glibenclamide. J Cardiovasc Pharmacol 33 (1999) 323-334
176. Wolleben C.D., Sanguinetti M.C., and Siegl P.K. Influence of ATP-sensitive potassium channel modulators on ischemia-induced fibrillation in isolated rat hearts. J Mol Cell Cardiol 21 (1989) 783-788
177. Yan G.X., and Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 98 (1998) 1928-1936
178. Yan G.X., Yamada K.A., Kleber A.G., McHowat J., and Corr P.B. Dissociation between cellular K+ loss, reduction in repolarization time, and tissue ATP levels during myocardial hypoxia and ischemia. Circ Res 72 (1993) 560-570
179. Yazar A., Polat G., Levant A., Kaygusuz A., Camdeviren H., and Buyukafsar K. Effects of glibenclamide, metaformin and insulin on the incidence and latency of death by ouabian-induced arrhythmias. Pharmacol Res 45 (2002) 183-187
180. Zhang H.I., Li Y.S., Fu S.X., and Yang X.P. Effects of glibenclamide and tolbutamine on ischemia-induced and ouabain-induced arrhythmias and membrane potentials of ventricular myocardium from rat and guinea-pig. Acta Pharmcol Sinica 12 (1991) 398-402
181. Zheng Z.J., Croft J.B., Giles W.H., and Mensah G.A. Sudden cardiac death in the United States, 1989 to 1998. Circulation 104 (2001) 2158-2163
182. Zhu B.M., Miyamoto S., Nagawa Y., Wajima T., and Hashimoto K. Effect of sarcolemmal K-ATP blocker HMR 1098 on arrhythmias induced by programmed electrical stimulation in canine old myocardial infarction model: comparison with glibenclamide. J Pharmacol Sci 93 (2003) 106-113
183. Zipes D.P., and Wellens H.J. Sudden cardiac death. Circulation 98 (1998) 2334-2351